Clinical Significance of Joint Detection of Serum VEGF, SIL-2R and HGF in Patients with Primary Hepatocellular Carcinoma before and after Percutaneous Microwave Coagulation Therapy

  • Chen, Ji-Dong (Department of Interventional Ultrasound, Sichuan Provincial People's Hospital) ;
  • Xiong, Yan-Qun (Department of Operating Room, Sichuan Provincial People's Hospital) ;
  • Dong, Ke (Department of General Surgery, Sichuan Provincial People's Hospital) ;
  • Luo, Jun (Department of Interventional Ultrasound, Sichuan Provincial People's Hospital) ;
  • Yue, Lin-Xian (Department of Interventional Ultrasound, Sichuan Provincial People's Hospital) ;
  • Chen, Qin (Department of Interventional Ultrasound, Sichuan Provincial People's Hospital)
  • Published : 2014.06.15


Objective: To investigate the changes of serum vascular endothelial growth factor (VEGF), soluble interleukin-2 receptor (SIL-2R) and hepatocyte growth factor (HGF) contents in patients with primary hepatocellular carcinoma (HCC) before and after percutaneous microwave coagulation therapy (PMCT) and determine their clinical significance. Materials and Methods: Fasting venous blood (3 mL) from 81 patients with primary HCC diagnosed by pathology was collected in the mornings 1 day before PMCT, and 1 day, 7 days and 1 month after PMCT, and then the serum was separated and stored in $-70^{\circ}C$. The contents of VEGF, SIL-2R and HGF were detected by enzyme linked immunosorbent assay (ELISA). Results: The serum VEGF, SIL-2R and HGF contents in 81 patients with primary HCC had obviously dynamic changes before and after PMCT. By comparison to 1 day after PMCT with pre-operation, there was no statistical significance regarding VEGF and SIL-2R contents (P>0.05), but HGF content showed significant difference (P<0.01). Compared with pre-operation, VEGF, SIL-2R and HGF contents 7 days and 1 month after PMCT all manifested significant differences (P<0.01). By comparison to 7 days with 1 month after PMCT, there was no statistical significance regarding the VEGF content (P>0.05), whereas SIL-2R and HGF contents showed significant change (P<0.01). Conclusions: The contents of serum VEGF, SIL-2R and HGF have obviously dynamic changes in primary HCC before and after PMCT, and their joint detection is expected to be an effective hematologic evaluation index of PMCT for primary HCC.


  1. Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9.
  2. Abdelgawad IA, Mossallam GI, Radwan NH, et al (2013). Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9.
  3. Ahluwalia A, Tarnawski AS (2012). Critical role of hypoxia sensor--HIF-1$\alpha$ in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem, 19, 90-7.
  4. Aydemir TB, Sitren HS, Cousins RJ (2012). The zinc transporter Zip14 influences c-Met phosphorylation and hepatocyte proliferation during liverregeneration in mice. Gastroenterology, 142, 1536-46.
  5. Cai XY, Wang JX, Yi Y, et al (2014). Low counts of ${\gamma}{\delta}$ T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev, 15, 775-80.
  6. Chittmittrapap S, Chieochansin T, Chaiteerakij R, et al (2013). Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev, 14, 7675-9.
  7. Cui J, Dong BW, Liang P, et al (2005). Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma. World J Gastroenterol, 11, 3027-33.
  8. Dong BW, Zhang J, Liang P, et al (2002). Influencing factors of local immunocyte infiltration in hepatocellular carcinoma tissues pre- and post-percutaneous microwave coagulation therapy. Zhonghua Yi Xue Za Zhi, 82, 393-7.
  9. Fulop AK, Pocsik E, Brozik M, et al (2001). Hepatic regeneration induces transient acute phase reaction: systemic elevation of acute phase reactants andsoluble cytokine receptors. Cell Biol Int, 25, 585-92.
  10. Eisele RM, Denecke T, Glanemann M, et al (2014). Minimal-invasive microwave coagulation therapy for liver tumours: laparoscopic andpercutaneous access. Zentralbl Chir, 139, 235-43.
  11. Eller T, Aluoja A, Maron E, et al (2009). Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina, 45, 971-7.
  12. El Kassas HY, Attia AA (2014). Bactericidal application and cytotoxic activity of biosynthesized silver nanoparticles with an extract of the red seaweed Pterocladiella capillacea on the HepG2 cell line. Asian Pac J Cancer Prev, 15, 1299-306.
  13. Fan FT, Shen CS, Tao L, et al (2014). PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation. Asian Pac J Cancer Prev, 15, 1961-70.
  14. Gupta SP, Mittal A, Sathian B, et al (2013). Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev, 14, 7331-3.
  15. Gustafsson A, Andersson M, Lagerstedt K, et al (2010). Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2. Int J Oncol, 36, 469-78.
  16. Hao YX, Wang JP, Zhao LF (2013). Associations between three common microRNA polymorphisms and hepatocellular carcinoma risk in Chinese. Asian Pac J Cancer Prev, 14, 6601-4.
  17. Hombach AA, Abken H (2012). Antibody-IL2 fusion proteins for tumor targeting. Methods Mol Biol, 907, 611-26.
  18. Kanazawa S, Yamaguchi K, Kinoshita Y, et al (2006). Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. J Cancer Res Clin Oncol, 132, 719-25.
  19. Hu RH, Lee PH, Yu SC, et al (1999). The serum hepatocyte growth factor before and after resection for hepatocellular carcinoma. Hepatogastroenterology, 46-48, 1842-7.
  20. Ji D, Lu ZT, Li YQ, et al (2014). MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 999-1003.
  21. Jeng JE, Tsai MF, Tsai HR, et al (2014). Impact of chronic hepatitis B and hepatitis C on adverse hepatic fibrosis in hepatocellular carcinoma related to betel quid chewing. Asian Pac J Cancer Prev, 15, 637-42.
  22. Li T, Xu WS, Wu GS, et al (2014). Platycodin D induces apoptosis, and inhibits adhesion, migration and invasion in HepG2 hepatocellular carcinoma cells. Asian Pac J Cancer Prev, 15, 1745-9.
  23. Miyata K, Taniguchi H, Takeuchi K, et al (1996). Weight of resected liver is positively correlated with serum hHGF level. Hepatogastroenterology, 43, 1589-93.
  24. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9.
  25. Pircher A, Wellbrock J, Fiedler W, et al (2014). New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules. Oncology, 86, 46-52.
  26. Tang YH, Zhu WJ, Wen TF (2014). Influence of clinically significant portal hypertension on hepatectomy for hepatocellular carcinoma: a meta-analysis. Asian Pac J Cancer Prev, 15, 1649-54.
  27. Zhan P, Qian Q, Yu LK (2013). Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis. Hepatobiliary Surg Nutr, 2, 148-55.
  28. Wang NY, Wang C, Li W, et al (2014). Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev, 15, 1539-44.
  29. Xiong YQ, Chen JD (2013). The surgical care of Ultrasound-guided percutaneous microwave coagulation therapy (PMCT) of liver cancer. Pract J Clin Med, 10, 146-7.
  30. Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-6.
  31. Zhang SC, Liang MK, Huang GL, et al (2014). Inhibition of SMP30 gene expression influences the biological characteristics of human Hep G2 cells. Asian Pac J Cancer Prev, 15, 1193-6.
  32. Zhu WJ, Huang CY, Li C, et al (2013). Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 14, 7101-6.

Cited by

  1. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations vol.21, pp.6, 2014,
  2. Diagnostic and Therapeutic Implications of the Vascular Endothelial Growth Factor Family in Cancer vol.16, pp.5, 2015,
  3. Anti-tumor and Chemoprotective Effect of Bauhinia tomentosa by Regulating Growth Factors and Inflammatory Mediators vol.16, pp.18, 2016,
  4. Biomarkers in hepatocellular carcinoma: an overview vol.11, pp.6, 2017,